drugset / Trial / NCT00148382

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

NCT00148382

Phase 1 Completed 80 enrolled Alizyme
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Timeline

Start
2005-04
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject cetilistat Small molecule 40 mg
Subject cetilistat Small molecule 80 mg
Subject cetilistat Small molecule 120 mg
Subject cetilistat Small molecule 240 mg

Indications